Moderna, Inc. (MRNA) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2023
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, Moderna, Inc. (MRNA) trades at a price-to-earnings ratio of -5.8x, with a stock price of $53.57 and trailing twelve-month earnings per share of $-7.99.
The current P/E is 123% below its 5-year average of 24.7x. Over the past five years, MRNA's P/E has ranged from a low of 4.3x to a high of 104.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, MRNA trades at a 124% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, MRNA trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MRNA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Vaccines and Infectious Disease peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
SCNIScinai Immunotherapeutics Ltd. | $3B | 0.1Lowest | -Best | +136% |
NVAXNovavax, Inc. | $2B | 3.9 | -Best | +310%Best |
CVACCureVac N.V. | $1B | 6.5 | -Best | +161% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $121.50 | $2.73 | 44.5x | +80% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $153.58 | $11.59 | 13.3x | -46% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $179.62 | $19.97 | 9.0x | -64% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $118.25 | $27.64 | 4.3x | -83% |
| FY2022 Q2 | $142.85 | $32.81 | 4.4x | -82% | |
| FY2022 Q1 | $172.26 | $34.03 | 5.1x | -80% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $253.98 | $28.29 | 9.0x | -64% |
| FY2021 Q3 | $384.86 | $16.31 | 23.6x | -4% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $234.98 | $8.02 | 29.3x | +19% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $130.95 | $1.25 | 104.8x | +324% |
Average P/E for displayed period: 24.7x
See MRNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MRNA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare MRNA vs AGIO
See how MRNA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is MRNA stock overvalued or undervalued?
MRNA trades at -5.8x P/E, below its 5-year average of 24.7x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does MRNA's valuation compare to peers?
Moderna, Inc. P/E of -5.8x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is MRNA's PEG ratio?
MRNA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2023.